Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Misses Estimates By $0.31 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31), Briefing.com reports. The business had revenue of $108.83 million for the quarter, compared to the consensus estimate of $116.03 million. Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 421.88%. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($2.33) EPS.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE opened at $42.75 on Friday. Ultragenyx Pharmaceutical has a 12 month low of $31.52 and a 12 month high of $54.98. The company’s 50-day moving average price is $47.25 and its two-hundred day moving average price is $44.14.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 11,509 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the completion of the transaction, the executive vice president now directly owns 252,823 shares of the company’s stock, valued at $12,623,452.39. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Ultragenyx Pharmaceutical news, Director Matthew K. Fust sold 12,195 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $50.88, for a total value of $620,481.60. Following the completion of the transaction, the director now directly owns 14,860 shares of the company’s stock, valued at $756,076.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $49.93, for a total transaction of $574,644.37. Following the completion of the transaction, the executive vice president now directly owns 252,823 shares of the company’s stock, valued at $12,623,452.39. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,116 shares of company stock valued at $1,645,983. Insiders own 6.80% of the company’s stock.

Analysts Set New Price Targets

RARE has been the topic of a number of recent research reports. Canaccord Genuity Group raised their price target on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. JPMorgan Chase & Co. lifted their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. Robert W. Baird lifted their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. Wedbush dropped their target price on shares of Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $107.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus price target of $88.00.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.